Bed Bath & Beyond (BBBY)
$12.11 0.11 (0.92%)
18:36 EDT BBBY Stock Quote Delayed 30 Minutes
Previous Close $12.11
Market Cap 1.70B
PE Ratio 4.28
Volume (Avg. Vol.) 9.58M
Day's Range 11.69 - 12.21
52-Week Range 3.43 - 17.79
Dividend & Yield 0.62 (5.12%)
BBBY Stock Predictions, Articles, and Bed Bath & Beyond News
- From InvestorPlace
- From the Web
The coronavirus pandemic has been a huge headwind for retail stocks, but these five winning retailers are worth buying amid the frenzy.
Wall Street thought Bed Bath & Beyond's earnings were awful. They weren't. They actually show why BBBY stock can triple from here.
Roku, Virgin Galactic, Advanced Micro Devices, Walgreens and Bed Bath & Beyond were our top stock trades from Thursday.
Bed Bath and Beyond (BBBY) earnings for the retail company's fiscal first quarter of 2020 have BBBY stock falling after-hours Wednesday.
With the fiscal data about to be released, BBBY stock traders must weigh the company's challenges against the possibility of an earnings beat.
Bed Bath & Beyond stock could glide toward $20 this year if management boosts profits and consumer spending continues to rebound.
Depressed BBBY stock could surge over the next 12 months and beyond, as turnaround initiatives gain momentum alongside resurgent consumer spending.
Rotation into small-cap stocks this week is shining a light on beaten-down equities. Here are three of the best-looking trade ideas.
These high-risk stocks also offer tons of reward, but are you flipping a coin between boom or bust? How much risk can you stand?
Bed Bath & Beyond (BBBY) earnings for the retail company's fiscal fourth quarter of 2019 have BBBY stock soaring after-hours Wednesday.
Snap, Pinterest, Bed Bath & Beyond, Baidu and Alibaba were our top stock trades for Thursday. That said, here's a look at the charts.
CEO Mark Tritton laid off people, sold and leased back his stores, and promised a new executive team. Then the virus hit.
Due to global panic over the coronavirus, economies everywhere have shuttered. Very simply, this is not at all a conducive environment for these retail stocks.
Much like Tesla, these heavily shorted stocks could skyrocket higher on the back of short squeezes over the next few months.
Bed Bath & Beyond (BBBY) news for Wednesday concerning a sales update for the fourth quarter of 2019 isn't doing BBBY stock any favors.
Looking for a stock that will double or triple in 2020? These 10 lottery stocks have a realistic opportunity to do just that.
From Analyst Ratings
BTIG analyst Ryan Zimmerman maintained a Buy rating on Organogenesis Holdings (ORGO – Research Report) today and set a price target of $8.00. The company’s shares closed last Thursday at $3.66. According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 13.8% and a 57.1% success rate. Zimmerman covers the Healthcare sector,
From Seeking Alpha
China Finance Online (NASDAQ:JRJC) +148% on agreement with Dow Jones.Capitala Finance (NASDAQ:CPTA) +53% announces portfolio activity.Immutep (NASDAQ:IMMP) +52% on announcing United States patent grant for IMP701 antibody.NextDecade (NASDAQ:NEXT) +50% as Rio Grande LNG to cut costs by using five trains, not six.Sphere 3D (NASDAQ:ANY) +45%.Can-Fite BioPharma (NYSEMKT:CANF) +39% on advancing piclidenoson in COVID-19.ReWalk Robotics (NASDAQ:RWLK) +30% on announcing the Centers for Medicare and Medicaid Services issued Healthcare Common Procedure Coding System Level II Code K1007 in response to the application.VBI Vaccines (NASDAQ:VBIV) +19%.Organogenesis (NASDAQ:ORGO) +19% on Q2 preliminary revenue.Moderna (NASDAQ:MRNA) +17% as coronavirus vaccine induces immune response, phase 1 results show.ATIF Holdings (NASDAQ:ATIF) +16%.Everi Holdings (NYSE:EVRI) +14%.China Natural Resources (NASDAQ:CHNR) +12%.Dave & Buster's Entertainment (NASDAQ:PLAY) +12%.RTI Surgical Holdings (NASDAQ:RTIX) +11%.Wipro (NYSE:WIT) +11%.TherapeuticsMD (NASDAQ:TXMD) +10% expands access to AnnoveraInfosys (NYSE:INFY) +10% on Q1 results.Lion Financial (NASDAQ:LGHL) +10%.Jiayin (NASDAQ:JFIN) +9%.Gol Linhas Aereas Inteligentes S.A.
Navellier RatingsPowered by Portfolio Grader